Rheumatoid arthritis (RA) is an autoimmune disease characterized by both the presence of autoantibodies (either rheumatoid factor or those against citrullinated protein/peptide) and the chronic infi ltration of leukocytes into synovial tissue and fl uid. Th e latter is thought to be driven by interactions between chemokines and their G-protein-coupled receptors. Chemokines are known to play important roles in angiogenesis and lymphoid organization, and their expression patterns have been used as markers to identify a subset of lymphocytes and monocytes. As such, chemokines and their receptors have been deemed reasonable targets for the development of new RA treatments.
In a recent article in Arthritis Research & Th erapy, Fleishaker and colleagues [1] reported on the results of a clinical trial of a chemokine receptor antagonist in the treatment of patients with RA. Chemokines are classifi ed into CXC, CC, C, and CX3C supergene families according to the number and spacing of conserved cysteines. C-C chemokine-receptor type 5 (CCR5) is abundantly expressed in the RA synovium and T helper-cell type 1 infl ammatory infi ltrates, and is bound by macrophage infl ammatory protein (MIP)-1α (CCL3), MIP-1β (CCL4), and RANTES (regulated upon activation, normal T cell expressed, and secreted; CCL5) [2] . A CCR5-defi cient mouse model showed reduced bacterial clearance and was protected against endotoxin-induced systemic infl am mation and other enhanced immune reactions [3] . Further, although still controversial, a single nucleotide polymorphism resulting in the production of a nonfunctional receptor (CCR5-Δ32) protected against RA.
Th ese fi ndings have spurred the development of several CCR5 inhibitors. However, in a randomized, double-blind, placebo-controlled clinical trial, Fleishaker and colleagues [1] reported that a CCR5 antagonist (maraviroc), approved for use in HIV patients because CCR5 is the major coreceptor for HIV-1 entry into cells, was ineff ective in treating patients with RA who had shown inadequate responses to methotrexate (MTX). Given that their study found no signifi cant clinical effi cacy as evaluated based on American College of Rheumatology responder rates or changes from baseline in Disease Activity Score 28-4 C-reactive Protein (DAS28-4 (CRP)), the study was terminated [1] . Similarly, two additional CCR5 antagonists, SCH351125 and AZD5672, respectively tested on RA [4] and MTX-refractory RA patients [5] , also failed to demonstrate clinical effi cacy. Moreover, neither CCR2nor CCR5-blocking antibodies were able to inhibit synovial fl uid-induced monocyte chemotaxis [6] . Th erefore, CCR5 appears not to be a desirable target in RA treatment.
Th e above-described failures in using CCR5 inhibitors to treat RA may be explained by the multiple functions of CCR5 and redundancies in the chemokine system. However, although the expression of chemokines and their receptors has been believed to be redundant for decades, evidence shows that this may not be the case [7] . Instead, like most developmental processes, a strict temporal and spatial control of their expression could be Abstract Fleishaker and colleagues reported on a doubleblind placebo controlled clinical trial of a C-C chemokine-receptor type 5 (CCR5) antagonist, maraviroc, in rheumatoid arthritis (RA) patients with inadequate response to methotrexate, showing that it was ineff ective. Two additional CCR5 antagonists, SCH351125 and AZD5672, also failed to demonstrate clinical effi cacy. In addition, CCR5-blocking antibodies could not inhibit synovial fl uid-induced monocyte chemotaxis. Thus, CCR5 appears not to be a desirable target in RA treatment. Given the multiple functions of CCR5, redundancies in the chemokine system, and patient selection in the trial, we overview the recent understanding for chemokine receptor blockade in the treatment of RA critical in RA pathogenesis. A more fundamental understanding of the pathogenesis and pathophysiology of each RA patient may be needed in order to achieve precise control of the disease through manipulation of the chemo kine system. Th us, whether or not drugs are adminis tered to the right patients, at the right time, and with a suffi cient dosing regimen in clinical trials is critical.
As for the dosing regimen, that based on conventional pharmacokinetics/pharmacodynamics methods may not have been suffi cient to block targeting receptors more than 95% of the time. A recent review underscored the impor tance of maintaining dose levels suffi ciently above coverage levels for serum A10-receptors [7] . Th e maximum dosing may be partly limited by non-specifi c toxicity, such as liver dysfunction, of low molecular weight chemicals and the recycling of CCR5 molecules via the trans-Golgi network [8] . Although the clinical trials targeting infl ammatory cytokines such as tumor necrosis factor or interleukin-6 have been consistently positive, while those targeting chemokines have seldom been positive, this may be partly attributable to the diff erences between biological agents and low molecular weight chemicals, in addition to those between infl amma tory cytokines and chemokines. Even with biological agents against tumor necrosis factor, we recently demonstrated via a sub-analysis of the RISING study (a prospective, randomized, double-blind study to compare the effi cacy and safety of 10 mg/kg infl iximab with those of 3 mg/kg infl iximab treatment in MTX-refractory RA patients) that the dose of infl iximab required to sufficiently neutralize tumor necrosis factor dramatically diff ers among RA patients [9] . Th erefore, even when CCR5 inhibitors may be potentially eff ective for a small fraction of RA patients, the appropriate dosing regimen of CCR5 inhibitors to achieve sustained receptor occupancy above a suffi cient level might be crucial in the successful treatment of RA, but not of HIV infection.
While fi ndings regarding RA treatment with CCR5 inhibitors have thus far proven negative, these results still represent an important milestone in the development of target therapies for RA and other systemic autoimmune and infl ammatory diseases.
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